Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it has expanded an existing program in Spain to increase access to local testing...
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of...
Conditional approval based on data from Phase 3 PROpel trial MISSISSAUGA, ON, July 13, 2023 /CNW/ - Health Canada has granted a Notice of Compliance with Conditions (NOC/c) for Lynparza® (olaparib)...
Approval based on the DESTINY-Breast04 results which showed Enhertu reduced risk of disease progression or death by 50 per cent and increased overall survival by more than six months versus...
Global initiative aimed at creating healthcare systems that are more resilient and 'future-ready' TORONTO, June 7, 2022 /CNW/ - Today, we're proud to announce the launch of the Partnership for Health ...
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced nomination of the...
BenevolentAI, a leading clinical-stage AI drug discovery company, announced that AstraZeneca has added a novel target for idiopathic pulmonary fibrosis (IPF), discovered using BenevolentAI's...
International Process Plants (IPP), a global buyer and seller of pharmaceutical and biopharmaceutical manufacturing facilities and equipment, announced its client AGC Biologics' successful Q2/20...
MISSISSAUGA, ON, Sept. 30, 2019 /CNW/ - AstraZeneca Canada announced today that Health Canada has approved the expanded use of Symbicort® Turbuhaler® (budesonide/formoterol) for the treatment of mild ...
Fewer MACE events observed with Forxiga vs. placebo, but this finding did not reach statistical significance No imbalance in amputations, fractures, bladder cancer or Fournier's gangrene with Forxiga ...
Phase III PACIFIC data presented at the IASLC 2018 World Conference on Lung Cancer in Toronto shows 32 per cent reduced risk of death for patients treated with Imfinzi compared to standard of care...
Pivotal FLAURA study demonstrated 18.9 months median progression-free survival for patients receiving Tagrisso versus 10.2 months compared with earlier generation EGFR tyrosine kinase inhibitors...
Lynparza has been shown to reduce the risk of disease progression or death by 42 per cent compared to standard of care chemotherapy.i MISSISSAUGA, May 10, 2018 /CNW/ - AstraZeneca today announced...
Patients receiving Imfinzi in the PACIFIC clinical trial lived for nearly one year without their disease progressing versus placebo MISSISSAUGA, ON, May 9, 2018 /CNW/ - AstraZeneca Canada today...
Approval granted based on promising tumour response rate and duration of response MISSISSAUGA, ON, Nov. 6, 2017 /CNW/ - AstraZeneca Canada today announced that Health Canada has approved Imfinzi®...
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced the launch of SILIQ™ (brodalumab) Injection during the Summer American Academy of Dermatology (AAD) meeting taking ...
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced it will acquire the U.S. rights to Toprol-XL® (metoprolol succinate) and its...
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX:VRX) ("Valeant") today announced that its affiliate and AstraZeneca (LSE/SSE/NYSE: AZN) have amended Valeant's license for brodalumab,...
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced that it has received notification from the U.S. Food and Drug Administration (FDA)...
Eli Lilly and Company (NYSE: LLY) and AstraZeneca today announced that AMARANTH, a Phase 2/3 study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a...
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its affiliate has entered into a collaboration agreement with AstraZeneca under which Valeant was granted an...
ASSESS shows plasma circulating tumour DNA (ctDNA) testing for EGFR mutation is a viable alternative to tumour biopsy IGNITE supports value of EGFR mutation testing in all patients with advanced...
LONDON, June 19, 2014 /CNW/ - AstraZeneca today announced that the New England Journal of Medicine (NEJM) has published results of two pivotal Phase III studies – KODIAC-4 and KODIAC-5 of naloxegol,...
CHICAGO, May 31, 2014 /CNW/ - Data from the ongoing Phase I AURA study in patients with epidermal growth factor receptor mutation positive (EGFRm+), advanced non-small cell lung cancer (NSCLC),...
Quebec's recent decision to introduce a maximum price for one drug class will lead to public drug plan patients receiving the cheapest drugs in that class, even if their doctor has prescribed a...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.